In a significant move to bolster its diagnostic offerings, Tecan Group has announced the acquisition of certain assets from Cisbio Bioassays SAS, part of Revvity Inc. This transaction includes the procurement of manufacturing rights for four essential ELISA kits, comprising two in vitro diagnostic (IVD) tools and two research-use-only (RUO) kits. To maintain continuity during the transition period, IBL International GmbH, a subsidiary of Tecan, has entered into a distribution agreement with Cisbio to ensure these kits remain accessible to customers. Once the transfer is finalized, IBL will take over all aspects of production, distribution, and regulatory compliance.

The acquisition encompasses several critical ELISA kits designed for both clinical diagnostics and research applications. Among them is the CGA-ELISA-NG, a CE-marked IVD product used to detect neuroendocrine tumors by measuring chromogranin A levels in adults. Another notable kit is the P3NP-ELISA, which evaluates collagen III synthesis to monitor liver fibrosis risks in psoriasis patients undergoing methotrexate therapy. Additionally, there are two RUO versions of these kits aimed at advancing scientific exploration.

By integrating these products into its portfolio, Tecan aims to sustain their availability while adhering to stringent quality and regulatory benchmarks. The decision reflects Tecan's dedication to providing top-tier solutions that meet evolving laboratory needs. Mukta Acharya, Head of Tecan’s Life Sciences Business, emphasized the importance of this strategic purchase in enhancing Tecan's specialty diagnostics lineup.

As regulatory landscapes shift, Tecan remains committed to expanding its range of compliant, reliable products. This collaboration with Cisbio highlights a proactive approach to ensuring laboratories have access to cutting-edge technologies now and in the future. By incorporating these vital ELISA kits, Tecan strengthens its position as a leader in the diagnostic field, reinforcing its reputation for delivering high-quality, innovative solutions.

This acquisition not only underscores Tecan's strategic vision but also solidifies its commitment to supporting global healthcare advancements through robust diagnostic capabilities. With the addition of these kits, Tecan continues to lead the way in meeting the diverse and complex demands of modern medical diagnostics.